{"id":2865,"date":"2026-09-03T09:00:00","date_gmt":"2026-09-03T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2865"},"modified":"2026-09-04T16:45:31","modified_gmt":"2026-09-04T20:45:31","slug":"clym116-shows-durable-april-suppression","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2865","title":{"rendered":"CLYM116 Shows Durable APRIL Suppression"},"content":{"rendered":"

Company:<\/strong> Climb Bio · Drug:<\/strong> CLYM116 · Trial Stage:<\/strong> Phase I (Healthy Volunteers) · Target Indication:<\/strong> IgA Nephropathy · Date:<\/strong> September 3, 2026<\/p>\n

\"CLYM116<\/p>\n

Summary<\/h4>\n

Climb Bio reported initial Phase I healthy-volunteer data for CLYM116, a pH-dependent APRIL “sweeper” antibody licensed from Beijing Mabworks. A single 320-mg subcutaneous dose produced greater than 90% free-APRIL suppression through week 10 and more than 75% at week 12, with approximately 60%-75% suppression of IgA, galactose-deficient IgA1 and IgM through 12 weeks. No serious, grade 3 or higher, dose-limiting or discontinuation-causing adverse events were reported. The pharmacology supports infrequent dosing, but no IgA-nephropathy efficacy data are available.<\/p>\n

What Happened<\/h4>\n

The randomized, placebo-controlled Phase I study enrolled 46 healthy volunteers across single- and multiple-ascending-dose cohorts; 35 received CLYM116 and 11 placebo. The company estimates a roughly 29-day half-life for the 320-mg multiple-dose regimen. Twenty-five treated participants and five placebo recipients reported at least one treatment-emergent event; treatment-related events occurred in eight treated participants. Injection-site reactions occurred in five and were grade 1. Climb has begun the open-label Phase II NAVIGATE-2 study in IgA nephropathy, testing an 800-mg loading dose followed by 400 mg every eight or twelve weeks. A 200-mg\/mL formulation permits a 400-mg dose in one subcutaneous injection. Initial patient data are expected in the first half of 2027, with a registrational study targeted for 2027 subject to regulatory feedback.<\/p>\n

Deep Analysis<\/h4>\n

Deep, sustained APRIL and pathogenic-IgA suppression after one dose is consistent with the intended bind-release-degrade-and-recycle mechanism. Quarterly maintenance could reduce injection burden relative to approved or late-stage competitors, though the 29-day half-life is projected from a small healthy-volunteer dataset and every-12-week exposure is model-supported rather than patient-validated; IgAN proteinuria and eGFR outcomes may not scale directly with circulating biomarker depth. Clinical validation of APRIL and BAFF\/APRIL inhibition reduces target risk and makes a differentiated regimen commercially relevant, but it also creates a demanding benchmark: CLYM116 must match or improve proteinuria, renal-function preservation, safety and convenience against therapies already approved or approaching market. The absence of hypogammaglobulinemia in 35 treated healthy volunteers is reassuring but insufficient to define infection and immunoglobulin risks during chronic dosing in kidney disease.<\/p>\n

Company and Product Background<\/h4>\n

Climb Bio develops medicines for immune-mediated diseases. CLYM116 originated at Beijing Mabworks Biotech and uses pH-dependent APRIL binding plus Fc engineering. The antibody binds APRIL in circulation, releases it after cellular uptake for lysosomal degradation and recycles through FcRn, aiming to clear repeated target molecules while extending exposure. IgA nephropathy is an immune-mediated glomerular disease driven in part by galactose-deficient IgA1 and corresponding autoantibodies that form kidney-depositing immune complexes. APRIL supports B-cell and plasma-cell survival and immunoglobulin class switching. Blocking APRIL can reduce pathogenic IgA production, but long-term value depends on preserving immune competence while slowing irreversible loss of renal function.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Trial<\/td>\nPhase I, 46 healthy volunteers (35 CLYM116, 11 placebo)<\/td>\n<\/tr>\n
Pharmacodynamics<\/td>\n>90% free-APRIL suppression through week 10; ~29-day half-life<\/td>\n<\/tr>\n
Secondary Suppression<\/td>\n60-75% IgA, gd-IgA1, IgM suppression through 12 weeks<\/td>\n<\/tr>\n
Safety<\/td>\nNo serious\/grade 3+\/DLT events; only grade 1 injection-site reactions<\/td>\n<\/tr>\n
Next Step<\/td>\nPhase II NAVIGATE-2 in IgAN underway; patient data expected H1 2027<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> Deep, single-dose APRIL and pathogenic-IgA suppression sustained through 12 weeks, combined with a clean early safety profile, supports an infrequent quarterly dosing regimen that could meaningfully reduce treatment burden relative to more frequently dosed competitors.<\/p>\n

Bear case:<\/strong> The dataset is limited to healthy volunteers with no IgA-nephropathy efficacy data, the projected half-life comes from a small cohort, and biomarker suppression may not translate proportionally into the proteinuria reduction and renal-function preservation that matter clinically.<\/p>\n

InSilens Take<\/h4>\n

CLYM116 has earned a credible differentiation hypothesis, not a best-in-class conclusion. The sweeper design produced unusually durable target and IgA suppression with clean early safety in healthy volunteers, and formulation work has reduced the regimen to a practical single injection. The decisive translation step is NAVIGATE-2: quarterly dosing must convert biomarker depth into proteinuria reduction and renal-function preservation without clinically meaningful immunoglobulin or infection liability.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Positive · Confidence:<\/strong> High on facts, Moderate-low on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

Climb Bio reported initial Phase I healthy-volunteer data for CLYM116, a pH-dependent APRIL “sweeper” antibody licensed from Beijing Mabworks. A single 320-mg subcutaneous dose produced greater than 90% free-APRIL suppression through week 10 and…<\/p>\n","protected":false},"author":1,"featured_media":2883,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[528,81,527,47],"class_list":["post-2865","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-april","tag-climb-bio","tag-clym116","tag-iga-nephropathy"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2865"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2865\/revisions"}],"predecessor-version":[{"id":2890,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2865\/revisions\/2890"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2883"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2865"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2865"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}